Shi Xiao San ameliorates the development of adenomyosis in an ICR mouse model

Ye,Juan; Cai,Xueting; Wang,Dawei; Zhang,Furong; Wang,Zhigang; Cao,Meng; Pang,Zhonghua; Yang,Jie; Yan,Huaijiang; Li,Jing; Cao,Peng; Hu,Chunping

doi:10.3892/etm.2020.8994

Shi Xiao San ameliorates the development of adenomyosis in an ICR mouse model

Authors:
- Juan Ye
- Xueting Cai
- Dawei Wang
- Furong Zhang
- Zhigang Wang
- Meng Cao
- Zhonghua Pang
- Jie Yang
- Huaijiang Yan
- Jing Li
- Peng Cao
- Chunping Hu
View Affiliations

Affiliations: Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing, Jiangsu 210028, P.R. China
Published online on: July 13, 2020 https://doi.org/10.3892/etm.2020.8994
Pages: 2845-2855

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The use of Shi Xiao San (SXS), composed of Pollen Typhae Angustifoliae and Faeces Trogopterori, can be traced back to the Song dynasty. Traditionally, SXS has been used to treat irregular menstruation, pelvic pain, progressive dysmenorrhea, and postpartum lochiorrhea. The management of adenomyosis (AM) is challenging and to the best of our knowledge there are currently no effective therapeutic strategies. Therefore, the aim of the present study was to investigate the effect of SXS on the development of adenomyosis in a mouse model. AM was induced in 60 neonatal female ICR mice by administering tamoxifen; 10 randomly selected mice were used for model identification via histopathological examination and 10 mice treated with the solvent alone were used as the normal controls. A total of sixty days after birth, the mice treated with AM were randomly divided into four groups and administered one of the following treatments: Low‑dose SXS (55 mg/kg); high‑dose SXS (110 mg/kg); danazol (1 mg/20 g body weight); or no treatment (model group); at the same time, the normal control group received no treatment. After 2 months of treatment, hotplate and tail‑ﬂick tests were used to assess the response to noxious thermal stimuli in the mice, and plasma samples were collected to measure corticosterone levels. Hematoxylin and eosin staining scores of myometrial infiltration and the number of AM nodules were evaluated. Furthermore, the expression of genes associated with AM‑related pain was also analyzed. The results from the present study indicated that treatment with SXS decreased myometrial infiltration, alleviated generalized hyperalgesia, and lowered plasma corticosterone levels in mice with induced AM. These findings suggest that SXS effectively attenuated the development of AM, and may serve as a promising treatment approach for AM treatment.

View Figures

View References

1	Munro MG: Classification and reporting systems for adenomyosis. J Minim Invasive Gynecol. 27:296–308. 2020.PubMed/NCBI View Article : Google Scholar
2	Yu O, Schulze-Rath R, Grafton J, Hansen K, Scholes D and Reed SD: Adenomyosis incidence, prevalence and treatment: United States population-based study 2006-2015. Am J Obstet Gynecol: doi:10.1016/j.ajog.2020.01.016.
3	Tomassetti C, Meuleman C, Timmerman D and D'Hooghe T: Adenomyosis and subfertility: Evidence of association and causation. Semin Reprod Med. 31:101–108. 2013.PubMed/NCBI View Article : Google Scholar
4	Koike N, Tsunemi T, Uekuri C, Akasaka J, Ito F, Shigemitsu A and Kobayashi H: Pathogenesis and malignant transformation of adenomyosis (review). Oncol Rep. 29:861–867. 2013.PubMed/NCBI View Article : Google Scholar : (review).
5	Jichan Nie, Xishi Liu and Guo SW: Promoter hypermethylation of progesterone receptor isoform B (PR-B) in adenomyosis and its rectification by a histone deacetylase inhibitor and a demethylation agent. Reprod Sci. 17:995–1005. 2010.PubMed/NCBI View Article : Google Scholar
6	Morelli M, Rocca ML, Venturella R, Mocciaro R and Zullo F: Improvement in chronic pelvic pain after gonadotropin releasing hormone analogue (GnRH-a) administration in premenopausal women suffering from adenomyosis or endometriosis: A retrospective study. Gynecol Endocrinol. 29:305–308. 2013.PubMed/NCBI View Article : Google Scholar
7	Bergeron C, Amant F and Ferenczy A: Pathology and physiopathology of adenomyosis. Best Pract Res Clin Obstet Gynaecol. 20:511–521. 2006.PubMed/NCBI View Article : Google Scholar
8	Grow DR and Filer RB: Treatment of adenomyosis with long-term GnRH analogues: A case report. Obstet Gynecol. 78:538–539. 1991.PubMed/NCBI
9	Saremi A, Bahrami H, Salehian P, Hakak N and Pooladi A: Treatment of adenomyomectomy in women with severe uterine adenomyosis using a novel technique. Reprod Biomed Online. 28:753–760. 2014.PubMed/NCBI View Article : Google Scholar
10	Pepas L, Deguara C and Davis C: Update on the surgical management of adenomyosis. Curr Opin Obstet Gynecol. 24:259–264. 2012.PubMed/NCBI View Article : Google Scholar
11	Taran FA, Stewart EA and Brucker S: Adenomyosis: Epidemiology, risk factors, clinical phenotype and surgical and interventional alternatives to hysterectomy. Geburtshilfe Frauenheilkd. 73:924–931. 2013.PubMed/NCBI View Article : Google Scholar
12	Hu SH, Cao BL, Liu X, et al: Drug use law of traditional chinese medicine in treating endometriosis. West J Tradit Chin Med. 31:87–90. 2018.(In Chinese).
13	Wang Y and Wei SB and Wei SB: The second stage therapy of TCM in treating 120 cases of adenomyosis of stagnation pattern of heat-dampness. West J Tradit Chin Med. 30:1–3. 2017.(In Chinese).
14	Liu Z, Li YH, Sun J, et al: Study of usages of Shixiao powder by ancient literature. J Ethnomedicine Ethnopharmacy. 27:7–10. 2018.
15	Zhou J and Qu F: Treating gynaecological disorders with traditional Chinese medicine: A review. Afr J Tradit Complement Altern Med. 6:494–517. 2009.PubMed/NCBI View Article : Google Scholar
16	Flower A, Liu JP, Lewith G, Little P and Li Q: Chinese herbal medicine for endometriosis. Cochrane Database Syst Rev. 5(CD006568)2012.PubMed/NCBI View Article : Google Scholar
17	Cheng C, Gui T, Huang MH, et al: Treatment of adenomyosis patients by bushen huoxue sanyu decoction: A clinical study. CJITWM. 34(11):1302–1305. 2014.PubMed/NCBI
18	Zhang L and Shi YP: Efficacy observation of ultrasonic conductometric acupoint penetration of Wenhua Zhitong recipe for adenomyosis patients. CJITWM. 36(1):54–58. 2016.PubMed/NCBI(In Chinese).
19	Chen Y, Zhu B, Zhang H, Liu X and Guo SW: Epigallocatechin-3-gallate reduces myometrial infiltration, uterine hyperactivity, and stress levels and alleviates generalized hyperalgesia in mice induced with adenomyosis. Reprod Sci. 20:1478–1491. 2013.PubMed/NCBI View Article : Google Scholar
20	Mao X, Wang Y, Carter AV, Zhen X and Guo SW: The retardation of myometrial infiltration, reduction of uterine contractility, and alleviation of generalized hyperalgesia in mice with induced adenomyosis by levo-tetrahydropalmatine (l-THP) and andrographolide. Reprod Sci. 18:1025–1037. 2011.PubMed/NCBI View Article : Google Scholar
21	Liu X and Guo SW: Valproic acid alleviates generalized hyperalgesia in mice with induced adenomyosis. J Obstet Gynaecol Res. 37:696–708. 2011.PubMed/NCBI View Article : Google Scholar
22	Mehasseb MK, Bell SC and Habiba MA: The effects of tamoxifen and estradiol on myometrial differentiation and organization during early uterine development in the CD1 mouse. Reproduction. 138:341–350. 2009.PubMed/NCBI View Article : Google Scholar
23	Zhang X, Yuan H, Deng L, Hu F, Ma J and Lin J: Evaluation of the efficacy of a danazol-loaded intrauterine contraceptive device on adenomyosis in an ICR mouse model. Hum Reprod. 23:2024–2030. 2008.PubMed/NCBI View Article : Google Scholar
24	Kida H: Histological analysis of spontaneous adenomyosis-like changes in recombinant inbred mouse uterus (SMXA mouse)--a novel animal model for adenomyosis. Nihon Sanka Fujinka Gakkai Zasshi. 46(4):323–330. 1994.PubMed/NCBI(In Japanese).
25	Yamada H, Shimada S and Fujimoto S: Endometriosis-adenomyosis mouse model induced by transvaginal pituitary transplantation. Nihon Rinsho. 59 (Suppl 1):221–224. 2001.PubMed/NCBI(In Japanese).
26	Li Y, Zhang SF, Zou SE, Xia X and Bao L: Accumulation of nerve growth factor and its receptors in the uterus and dorsal root ganglia in a mouse model of adenomyosis. Reprod Biol Endocrinol. 9(30)2011.PubMed/NCBI View Article : Google Scholar
27	Li X, Liu X and Guo SW: Clinical profiles of 710 premenopausal women with adenomyosis who underwent hysterectomy. J Obstet Gynaecol Res. 40:485–494. 2014.PubMed/NCBI View Article : Google Scholar
28	Cirpan T, Yeniel O, Ulukus M, Ozbal A, Gundem G, Ozsener S, Mete Itil I and Zekioglu O: Clinical symptoms and histopathological findings in subjects with adenomyosis uteri. Clin Exp Obstet Gynecol. 35:48–53. 2008.PubMed/NCBI
29	Shrestha A and Sedai LB: Understanding clinical features of adenomyosis: A case control study. Nepal Med Coll J. 14:176–179. 2012.PubMed/NCBI
30	Nie J, Liu X and Guo SW: Immunoreactivity of oxytocin receptor and transient receptor potential vanilloid type 1 and its correlation with dysmenorrhea in adenomyosis. Am J Obstet Gynecol. 202:346. e1–8. 2010.PubMed/NCBI View Article : Google Scholar
31	Guo SW, Mao X, Ma Q and Liu X: Dysmenorrhea and its severity are associated with increased uterine contractility and overexpression of oxytocin receptor (OTR) in women with symptomatic adenomyosis. Fertil Steril. 99:231–240. 2013.PubMed/NCBI View Article : Google Scholar
32	Taran FA, Weaver AL, Coddington CC and Stewart EA: Understanding adenomyosis: A case control study. Fertil Steril. 94:1223–1228. 2010.PubMed/NCBI View Article : Google Scholar
33	Chapman CR, Tuckett RP and Song CW: Pain and stress in a systems perspective: Reciprocal neural, endocrine, and immune interactions. J Pain. 9:122–145. 2008.PubMed/NCBI View Article : Google Scholar
34	Li SP, Zhao J and Yang B: Strategies for quality control of Chinese medicines. J Pharm Biomed Anal. 55:802–809. 2011.PubMed/NCBI View Article : Google Scholar
35	Reagan-Shaw S, Nihal M and Ahmad N: Dose translation from animal to human studies revisited. FASEB J. 22:659–661. 2008.PubMed/NCBI View Article : Google Scholar
36	Ascher SM, Imaoka I and Lage JM: Tamoxifen-induced uterine abnormalities: The role of imaging. Radiology. 214:29–38. 2000.PubMed/NCBI View Article : Google Scholar
37	Mori T, Yamasaki S, Masui F, Matsuda M, Sasabe H and Zhou YF: Suppression of the development of experimentally induced uterine adenomyosis by a novel matrix metalloproteinase inhibitor, ONO-4817, in mice. Exp Biol Med (Maywood). 226:429–433. 2001.PubMed/NCBI View Article : Google Scholar
38	Gui T, Chen C, Zhang Z, Tang W, Qian R, Ma X, Cao P and Wan G: The disturbance of TH17-Treg cell balance in adenomyosis. Fertil Steril. 101:506–514. 2014.PubMed/NCBI View Article : Google Scholar
39	Yan Li, Shaofen Zhang, Xian Xia and Enshi Zhou: Establishment of an ICR mouse model of adenomyosis by oral administration of Tamoxifen. Acta laboratorium animalis scientia sinica. 17(5):345–350. 2009.(In Chinese).
40	Bird CC, McElin TW and Manalo-Estrella P: The elusive adenomyosis of the uterus--revisited. Am J Obstet Gynecol. 112:583–593. 1972.PubMed/NCBI View Article : Google Scholar
41	Emge LA: The elusive adenomyosis of the uterus Its historical past and its present state of recognition. Am J Obstet Gynecol. 83:1541–1563. 1962.PubMed/NCBI View Article : Google Scholar
42	Mechsner S, Bartley J, Loddenkemper C, Salomon DS, Starzinski-Powitz A and Ebert AD: Oxytocin receptor expression in smooth muscle cells of peritoneal endometriotic lesions and ovarian endometriotic cysts. Fertil Steril. 83 (Suppl 1):1220–1231. 2005.PubMed/NCBI View Article : Google Scholar
43	Szallasi A: Vanilloid (capsaicin) receptors in health and disease. Am J Clin Pathol. 118:110–121. 2002.PubMed/NCBI View Article : Google Scholar
44	Lu AP, Jia HW, Xiao C and Lu QP: Theory of traditional Chinese medicine and therapeutic method of diseases. World J Gastroenterol. 10:1854–1856. 2004.PubMed/NCBI View Article : Google Scholar
45	Garcia L and Isaacson K: Adenomyosis: Review of the literature. J Minim Invasive Gynecol. 18:428–437. 2011.PubMed/NCBI View Article : Google Scholar
46	Taran FA, Weaver AL, Coddington CC and Stewart EA: Characteristics indicating adenomyosis coexisting with leiomyomas: A case-control study. Hum Reprod. 25:1177–1182. 2010.PubMed/NCBI View Article : Google Scholar
47	Levgur M, Abadi MA and Tucker A: Adenomyosis: Symptoms, histology, and pregnancy terminations. Obstet Gynecol. 95:688–691. 2000.PubMed/NCBI View Article : Google Scholar
48	Greaves P and White IN: Experimental adenomyosis. Best Pract Res Clin Obstet Gynaecol. 20:503–510. 2006.PubMed/NCBI View Article : Google Scholar
49	Zhu B, Chen Y, Zhang H, Liu X and Guo SW: Resveratrol reduces myometrial infiltration, uterine hyperactivity, and stress levels and alleviates generalized hyperalgesia in mice with induced adenomyosis. Reprod Sci. 22:1336–1349. 2015.PubMed/NCBI View Article : Google Scholar
50	Moriyama T, Higashi T, Togashi K, Iida T, Segi E, Sugimoto Y, Tominaga T, Narumiya S and Tominaga M: Sensitization of TRPV1 by EP1 and IP reveals peripheral nociceptive mechanism of prostaglandins. Mol Pain. 17(1:3)2005.PubMed/NCBI View Article : Google Scholar
51	Nie J and Liu X: Quercetin alleviates generalized hyperalgesia in mice with induced adenomyosis. Mol Med Rep. 16:5370–5376. 2017.PubMed/NCBI View Article : Google Scholar
52	Kurtais Y, Tur BS, Elhan AH, Erdogan MF and Yalçin P: Hypothalamic-pituitary-adrenal hormonal responses to exercise stress test in patients with rheumatoid arthritis compared to healthy controls. J Rheumatol. 33(8):1530–1537. 2006.PubMed/NCBI
53	Otake T, Ashihara M, Nishino J, Kato K, Fukaya S and Yoshida S: Stressors and rheumatoid arthritis: Changes in stressors with advances in therapeutic agents. Rheumatol Int. 33:887–891. 2013.PubMed/NCBI View Article : Google Scholar
54	Cuevas M, Flores I, Thompson KJ, Ramos-Ortolaza DL, Torres-Reveron A and Appleyard CB: Stress exacerbates endometriosis manifestations and inflammatory parameters in an animal model. Reprod Sci. 19:851–862. 2012.PubMed/NCBI View Article : Google Scholar
55	Ji GQ, Xu M, Yin H, et al: Study on Shixiaosan Granule on Toxicity in Rats. Acta Chinese Medicine. 6:985–988. 2017.
56	Li Q, Xie P, Bai CX, Cui JY, Jiang C and Wu YS: Mechanisms of Fufang Shixiao formula for experimental primary dysmenorrhea. Zhongguo Zhong Xi Yi Jie He Za Zhi. 36:1087–1090. 2016.PubMed/NCBI